Immune checkpoint inhibitors (ICIs) have shown limited efficacy in recurrent high-grade astrocytoma (rHGA). Here the authors report the results of a Phase 1/randomized Phase 2b trial of laser interstitial thermal therapy followed by anti-PD1 pembrolizumab in patients with rHGA.
- Jian L. Campian
- Son B. Le
- David D. Tran
